Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes.
- MeSH
- Aquaporin 4 genetics MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Immunoglobulin G MeSH
- Humans MeSH
- Neuromyelitis Optica * drug therapy genetics MeSH
- Receptors, IgG genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Aquaporin 4 MeSH
- FCGR3A protein, human MeSH Browser
- Antibodies, Monoclonal, Humanized MeSH
- Immunoglobulin G MeSH
- inebilizumab MeSH Browser
- Receptors, IgG MeSH
